EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke

Status Completed

Clinical Trial Summary

German stroke units are hesitating to use Aggrenox for secondary ischaemic stroke / transient ischaemic attack (TIA) prevention in a sub-acute treatment setting. They argue that clinical experience with sub-acute Aggrenox treatment is limited and poorly documented when compared with sub-acute acetylsalicylic acid (ASA) treatment. However, long term treatment (started after 3-6 months after stroke/TIA) with Aggrenox was safe and superior to ASA treatment in preventing recurrent strokes. There is no evidence for ASA to prevent from neurological progression after stroke during the first 3 months. Results from a cohort study suggest that starting Aggrenox within 72 hours after stroke predicts clinical improvement in the National Institute of Health Stroke Scale (NIHSS) at discharge from the hospital. Dipyridamole suppresses acute inflammatory responses to stroke.

This study is designed to investigate the tolerability and efficacy of a secondary stroke prevention treatment with Aggrenox when initiated within 24 hours of stroke onset on a stroke unit compared to later initiation after a 7 day ASA treatment and outside off a stroke unit setting.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00562588
Study type	Interventional
Source	Boehringer Ingelheim
Contact
Status	Completed
Phase	Phase 4
Start date	July 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05477238` - Oxygen Consumption in Post-stroke Patients During Various Walking Activities Compared to Healthy Controls	N/A
Completed	`NCT00046293` - ReoPro and Retavase to Treat Acute Stroke	Phase 2
Completed	`NCT04584645` - A Digital Flu Intervention for People With Cardiovascular Conditions	N/A
Completed	`NCT01116544` - Treatment of Chronic Stroke With AMES + EMG Biofeedback	N/A
Withdrawn	`NCT04991038` - Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients	N/A
Active, not recruiting	`NCT02563886` - Electrically Assisted Movement Therapy	N/A
Recruiting	`NCT02446730` - Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome	Phase 4
Completed	`NCT02141932` - Pocket-size Cardiovascular Ultrasound in Stroke	N/A
Completed	`NCT01915368` - Determining Optimal Post-Stroke Exercise (DOSE)	N/A
Recruiting	`NCT01769326` - Influence of Timing on Motor Learning	N/A
Recruiting	`NCT02557737` - Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities	Phase 3
Terminated	`NCT01705353` - The Role of HMGB-1 in Chronic Stroke	N/A
Completed	`NCT01423201` - Transient Ischemic Attack (TIA) Triage and Evaluation of Stroke Risk
Completed	`NCT01656876` - The Effects of Mirror Therapy on Upper Extremity in Stroke Patients	N/A
Completed	`NCT01182818` - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease	N/A
Withdrawn	`NCT00573092` - Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs	N/A
Completed	`NCT00542256` - tDCS and Physical Therapy in Stroke	N/A
Completed	`NCT00377689` - Evaluation of an Intervention Program Targeted at Improving Balance and Functional Skills After Stroke	Phase 2
Recruiting	`NCT00166751` - Sonographic Assessment of Laryngeal Elevation	N/A
Completed	`NCT00125619` - Internally Versus Externally Guided Body Weight-Supported Treadmill Training (BWSTT) for Locomotor Recovery Post-stroke	N/A

EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms